

[**Translation:** Please note that the following purports to be a translation from the Japanese original Notice of Resolution of the 115th Annual General Meeting of Shareholders for the Business Term Ended December 31, 2025 of Chugai Pharmaceutical Co., Ltd. prepared for the convenience of shareholders outside Japan with voting rights. However, in the case of any discrepancy between the translation and the Japanese original, the latter shall prevail.]

(Securities Code: 4519)

March 26, 2026

To the Shareholders:

**NOTICE OF RESOLUTION OF**  
**THE 115th ANNUAL GENERAL MEETING OF SHAREHOLDERS**

We are pleased to announce that the matters below were reported and resolved at the 115th Annual General Meeting of Shareholders of Chugai Pharmaceutical Co., Ltd. held today (the "AGM").

Yours very truly,

Osamu Okuda  
Representative Director, President & CEO  
CHUGAI PHARMACEUTICAL CO., LTD.  
(the "Company")  
5-1 Ukima 5-chome, Kita-ku, Tokyo  
1-1 Nihonbashi-Muromachi 2-chome,  
Chuo-ku, Tokyo

## PARTICULARS

### **Matters Reported:**

The Business Report for the Business Term (January 1, 2025 to December 31, 2025), Non-Consolidated Financial Statements for the Business Term, Consolidated Financial Statements for the Business Term, and the Report on the Results of Audit of the Consolidated Financial Statements by the Accounting Auditor and Audit & Supervisory Board

The contents of the above were reported.

### **Matters Resolved:**

#### **First Proposal**

#### **Appropriation of Surplus**

This item was approved and resolved as originally proposed. Appropriation of surplus for the end of the Term was decided to be JPY147 per share of common stock of the Company, and JPY241,919,872,593 in an aggregate amount.

#### **Second Proposal**

#### **Election of Nine (9) Directors**

This item was approved and resolved as originally proposed. Eight (8) Directors, namely, Osamu Okuda, Iwaaki Taniguchi, Hitoshi Iikura, Fumio Tateishi, Hideo Teramoto, Thomas Schinecker, Teresa A. Graham and Boris L. Zaïtra were reelected and assumed office as Directors. One (1) Director, namely, Kinuko Mitani was newly elected and assumed office as a Director.

Directors Fumio Tateishi, Hideo Teramoto and Kinuko Mitani are Outside Directors.

#### **Third Proposal**

#### **Revision of Stock Compensation System for Directors**

This item was approved and resolved as originally proposed.

– End –

## Directors and Audit & Supervisory Board Members

Based on the resolution by the Board of Directors and the Audit & Supervisory Board which were held after the AGM, Directors and Audit & Supervisory Board Members of the Company are as follows:

Representative Director, President & CEO	Osamu Okuda	reelected
Director, Executive Vice President & CFO	Iwaaki Taniguchi	reelected
Director, Executive Vice President	Hitoshi Iikura	reelected
Outside Director	Fumio Tateishi	reelected
Outside Director	Hideo Teramoto	reelected
Outside Director	Kinuko Mitani	newly elected
Director	Thomas Schinecker	reelected
Director	Teresa A. Graham	reelected
Director	Boris L. Zaïtra	reelected
Full-time Audit & Supervisory Board Member	Shigehiro Yamada	
Full-time Audit & Supervisory Board Member	Masayoshi Higuchi	
Outside Audit & Supervisory Board Member	Kenichi Masuda	
Outside Audit & Supervisory Board Member	Yumiko Waseda	
Outside Audit & Supervisory Board Member	Mami Yunoki	

Executive Officers of the Company, as of April 1, 2026, will be as follows:

Executive Vice President	Shinji Hidaka
Executive Vice President	Yoshiyuki Yano
Executive Vice President	Tsukasa Kusano
Executive Vice President	Kaori Ouchi
Executive Vice President	Norihisa Onozawa
Executive Vice President	Shoko Kimijima
Vice President	Shinya Takuma
Vice President	Naoya Fujihara
Vice President	Tomoyuki Igawa
Vice President	Kazuhiko Nishi